HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 49.55% from the company’s previous close.

Other equities analysts have also issued reports about the company. StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Saturday, December 28th. Rodman & Renshaw restated a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th. Finally, Benchmark lifted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 2.4 %

EBS opened at $10.03 on Friday. The firm has a market capitalization of $543.47 million, a P/E ratio of -2.45 and a beta of 1.60. Emergent BioSolutions has a one year low of $1.42 and a one year high of $15.10. The company has a fifty day moving average price of $9.33 and a 200-day moving average price of $9.08. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Hedge Funds Weigh In On Emergent BioSolutions

A number of large investors have recently modified their holdings of the company. Federated Hermes Inc. grew its position in Emergent BioSolutions by 1,314.0% during the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after acquiring an additional 253,960 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at $1,547,000. Oak Hill Advisors LP bought a new position in shares of Emergent BioSolutions during the 3rd quarter valued at $9,296,000. Assenagon Asset Management S.A. raised its position in Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Emergent BioSolutions in the 2nd quarter worth $1,576,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.